The Effect Of Iodopovidone Versus Bleomycin
Reza Bagheri1, Marzieh Noori2, Maryam Rajayi1, Davood Attaran1, Amir Mohammad Hashem Asna Ashari1, Shahrzad Mohammadzadeh Lari1, Reza Basiri1, Fariba Rezaeetalab1, Reza Afghani3, Maryam Salehi4.
1Lung Diseases Research Center, Mashhad University of Medical Sciences,, Mashhad, Iran, Islamic Republic of, 2Endoscopic and Minimally Invasive Surgery Research Center, Mashhad, Mashhad, Iran, Islamic Republic of, 35th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran, Mashhad, Iran, Islamic Republic of, 4Society Medicine, Ghaem Hospital, Mashhad University of Medical, Mashhad, Iran, Islamic Republic of.
Background: Malignant pleural effusion continues to be a common problem in patients with metastatic disease. This study was conducted to compare the efficacy and safety of bleomycin pleurodesis with povidone-iodine pleurodesis through a chest drain as palliative treatment for recurrent malignant pleural effusion. Methods: Sixty cancer patients (36 males and 24 females) with recurrent malignant pleural effusion were enrolled in a prospective randomized trial. Thirty patients received povidone-iodine pleurodesis and 30 received bleomycin pleurodesis. Age, sex, side of the primary pathology, treatment outcome (recurrence and relapse time), and complications were analyzed. Results: The mean age was 59.637.68 years in the povidone-iodine group and 57.979.27 years in the bleomycin group (p¼0.452). The complications were identical in both groups: 2 (6.7%) patients had chest pain, 2 (6.7%) had fever, and one (3.3%) had hypotension. There was a good response to therapy in 20 (66.7%) patients in the bleomycin group and 25 (83.3%) in the povidone-iodine group (p¼0.136). Conclusion: The results of this study indicate that povidone-iodine should be considered as a selective chemical agent to perform pleurodesis in patients with recurrent malignant pleural effusion because it has the same effect but costs less than bleomycin.
Back to 2020 ePosters